GDC-0575 is primarily investigated for its potential in cancer therapy, particularly as a checkpoint kinase 1 (CHK1) inhibitor. By targeting CHK1, it disrupts the DNA damage response pathway in cancer cells, preventing them from repairing DNA damage and leading to cell death. This makes it a promising candidate for enhancing the efficacy of DNA-damaging chemotherapies or radiation treatments. Research focuses on its use in treating various solid tumors and hematologic malignancies, often in combination with other anticancer agents to improve therapeutic outcomes. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in human patients.